LC-MS Bioanalysis of Endogenous Compounds as Biomarkers

Handbook of LC-MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations

Volumn , Issue , 2013, Pages 353-368

  Jian, Wenying ^a   Edom, Richard ^a   Weng, Naidong ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Assay validation; Bioanalysis; Biomarkers; Endogenous compounds; Fit for purpose; Liquid chromatography tandem mass spectrometry (LC MS)

Indexed keywords

DRUG PRODUCTS; ENZYME ACTIVITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

BIOANALYSIS; BIOMARKER COMPOUNDS; DEVELOPMENT PROCESS; ENDOGENOUS COMPOUND; FIT FOR PURPOSE; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; METHOD DEVELOPMENT; TANDEM MASS SPECTROMETRY;

BIOMARKERS;

EID: 84937493423     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118671276.ch28     Document Type: Chapter

References (47)

1. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27:633-641.
2. Boomsma F, Alberts G, Van Eijk L, Man In't Veld Aj, Schalekamp Ma. Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. Clin Chem 1993;39:2503-2508.
3. Booth B. Biomarkers Where we are going with method validation. Applied Pharmaceutical Analysis Meeting, Sept 11-14, 2011a, Boston, MA.
4. Booth B. When do you need a validated assay? Bioanalysis 2011b;3:2729-2730.
5. Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci USA 1979a;76:3213-3217.
6. Borgeat P, Samuelsson B. Metabolism of arachidonic acid in polymorphonuclear leukocytes: structural analysis of novel hydroxylated compounds. J Biol Chem 1979b;254:7865-7869.
7. Carr SA, Anderson L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin Chem 2005;54:1749-1752.
8. Chau CH, Rixe O, Mcleod H, Figg WD. Validation of analytical methods for biomarkers used in drug development. Clin Cancer Res 2008;14:5967-5976.
9. Ciccimaro E, Blair IA. Stable-isotope dilution LC-MS for quantitative biomarker analysis. Bioanalysis 2010;2:311-341.
10. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-87.
11. Cummings J, Raynaud F, Jones L, Sugar R, Dive C. Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer 2010;103:1313-1317.
12. Cummings J,Ward TH, GreystokeA, Ranson M, Dive C. Biomarker method validation in anticancer drug development. Br J Pharmacol 2008;153:646-656.
13. Desilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003;20:1885-1900.
14. Fast DM, Kelley M, Viswanathan CT, et al. Workshop report and follow-up-AAPSWorkshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples-implications of Crystal City recommendations. AAPS J 2009;11:238-241.
15. Fontaine N, Rosengren B. Directive 2001/20/EC of the European Parliament and of the Council: on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Commun 2001;L121:34-44.
16. Fretland DJW, Widomski DL, Anglin CP. 6-trans-Leukotriene B4 is a neutrophil chemotoxin in the guinea pig dermis. J Leukoc Biol 1991;49:283-288.
17. Goodenough AK, Onorato JM, Ouyang Z, et al. Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. Chem Res Toxicol 2011;24:1575-1585.
18. Goodsaid F, Frueh F. Biomarker qualification pilot process at the US food and drug administration. AAPS J 2007;9:E105-108.
19. Harmeyer J, Schlumbohm C. Effects of pharmacological doses of vitamin D3 on mineral balance and profiles of plasma vitamin D3 metabolites in horses. J Steroid Biochem Mol Biol 2004;89-90:595-600.
20. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 2003;140:802-808.
21. HMSO. US Statutory Instrument 2004 No. 1031. The Medicines for Human Use (Clinical Trials) Regulations. 2004.
22. HMSO. US Statutory Instrument 2006 No. 1928. The Medicines for Human Use (Clinical Trials) Regulations. 2006.
23. Houghton R, Horro Pita C,Ward I, Macarthur R. Generic approach to validation of small-molecule LC-MS/MS biomarker assays. Bioanalysis 2009;1:1365-1374.
24. Jemal M, Schuster A, Whigan DB. Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard. Rapid Commun Mass Spectrom 2003;17:1723-1734.
25. Jian W, Edom R, Weng N, Zannikos P, Zhang Z, Wang H. Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1687-1699.
26. Karlsen A, Blomhoff R, Gundersen TE. High-throughput analysis of vitamin C in human plasma with the use of HPLC with monolithic column and UV-detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005;824:132-138.
27. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004;1:189-195.
28. Lee JW. Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics. Bioanalysis 2009;1:1461-1474.
29. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23:312-328.
30. Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:1259-1271.
31. Lee JW, Weiner RS, Sailstad JM, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005;22:499-511.
32. Lee TH, Menica-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF. Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J Biol Chem 1984;259:2383-2389.
33. Li B, Sedlacek M, Manoharan I, et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005;70:1673-1684.
34. Li W, Cohen LH. Quantitation of endogenous analytes in biofluid without a true blank matrix. Anal Chem 2003;75: 5854-5859.
35. Li Y, Li Ac, Shi H, et al. Determination of S-phenylmercapturic acid in human urine using an automated sample extraction and fast liquid chromatography-tandem mass spectrometric method. Biomed Chromatogr 2006;20:597-604.
36. Matuszewski BK. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J Chromatogr B Analyt Technol Biomed Life Sci 2006;830:293-300.
37. Natarajan V, Schmid PC, Reddy PV, Schmid HH. Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J Neurochem 1984;42:1613-1619.
38. NIH. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69: 89-95.
39. Ocana MF, Neubert H. An immunoaffinity liquid chromatographytandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum. Anal Biochem 2010;399:202-210.
40. Pan J, Song Q, Shi H, et al. Development, validation and transfer of a hydrophilic interaction liquid chromatography/tandem mass spectrometric method for the analysis of the tobacco-specific nitrosamine metaboliteNNAL in human plasma at lowpicogram per milliliter concentrations. Rapid Commun Mass Spectrom 2004;18:2549-2557.
41. Quirke Jmecl, Adams CL, Van Berkel GV. Chemical derivatization for electrospray ionization mass spectrometry. 1. Alkyl halides, alcohols, phenols, thiols, and amines. Anal Chem 1994;66:1302-1315.
42. Sala A, Bolla M, Zarini S, Muller-Peddinghaus R, Folco G. Release of leukotriene A4 versus leukotriene B4 from human polymorphonuclear leukocytes. J Biol Chem 1996;271:17944-17948.
43. USFDA. Guidance for Industry: Bioanalytical validation. Guidance for Industry: Bioanalytical validation 2001;.
44. VanDe Merbel NC. Quantitative determination of endogenous compounds in biological samples using chromatographic techniques. Trends in Analytical Chemistry 2008;27:924-933.
45. Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. Pharm Res 2007;24:1962-1973.
46. Vogeser M. Quantification of circulating 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol 2010;121:565-573.
47. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-107.